Related Experiment Video
Updated: Jan 31, 2026
07:43
Assaying Proteasomal Degradation in a Cell-free System in Plants
Published on: March 26, 2014
15.1K
Ixazomib - the first oral proteasome inhibitor
Jingmei Xie1, Ning Wan2,3, Zhuoru Liang1
1a College of Pharmacy , Jinan University , Guangzhou , PR China.
Leukemia & Lymphoma
|January 8, 2019
Summary
Ixazomib is an oral proteasome inhibitor that significantly prolongs progression-free survival in relapsed/refractory multiple myeloma (RRMM). This first-in-class oral therapy offers a manageable safety profile for patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ixazomib is a proteasome inhibitor targeting the β5 subunit of the 20S proteasome.
- Relapsed/refractory multiple myeloma (RRMM) presents a significant unmet need for effective oral therapies.
Purpose of the Study:
- To review the clinical pharmacology, efficacy, tolerability, safety, and cost-effectiveness of ixazomib.
- To summarize the findings of the TOURMALINE-MM1 study regarding ixazomib in RRMM.
Main Methods:
- Review of clinical trial data, focusing on the TOURMALINE-MM1 study.
- Analysis of pharmacological properties, efficacy endpoints, adverse events, and cost-effectiveness.
Main Results:
- Ixazomib, combined with lenalidomide and dexamethasone, demonstrated prolonged progression-free survival (20.6 vs. 14.7 months) compared to placebo in RRMM patients.
- The drug exhibited a favorable and manageable safety profile with primarily low-grade hematological, digestive, and cutaneous events.
- Ixazomib is the first oral proteasome inhibitor approved for RRMM, offering a convenient treatment option.
Conclusions:
- Ixazomib represents a significant advancement in the oral treatment of relapsed/refractory multiple myeloma.
- Its efficacy, favorable safety profile, and oral administration support its role in managing RRMM.
- Ongoing research aims to further define ixazomib's utility in various treatment settings, including first-line, maintenance, and relapse therapies.
Related Concept Videos
02:18The Proteasome
10.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.2K
01:13The Proteasome
1.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
02:18The Proteasome
4.6K
4.6K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
575
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
575
01:17The Proteasome Structure
1.7K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.7K
01:52Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K